Granted Patent B2

US 12,410,262 · App. 18/174,981 · Granted Sep 9, 2025

Inventors: Daniel Richard Marshall (New Haven, CT); Johanna Marie Csengery (New Fairfield, CT); Robert John Maguire (New Haven, CT); Robert A. Volkmann (Mystic, CT)

Assignee: Cybrexa 2, Inc.

C07K19/00A61K31/4745A61P35/00C07D491/147C07D491/16C07D491/22C07K14/00A61K38/00C07K2319/00

Abstract

Claims (49)

1. A method of treating cancer in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I):

R 8 -Q-R 7   (I)

or a pharmaceutically acceptable salt thereof, wherein:

R 7 is a peptide;

R 8 is:

Q is:

R 1 and R 3 together with the carbon atoms to which they are attached form a C 3-14 cycloalkyl group or 4-14 membered heterocycloalkyl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C 1-4 alkyl, halo, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , and NR c1 C(O)NR c1 R d1 ;

R 2 and R 4 are each independently selected from H, C 1-4 alkyl, C 1-4 alkenyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, halo, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , and NR c1 C(O)NR c1 R d1 , wherein said C 1-4 alkyl, C 1-4 alkenyl, C 6-10 aryl, C 3-10 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO 2 , OR a1 , SR a1 , C(O)R b1 , C(O)NR c1 R d1 , C(O)OR a1 , OC(O)R b1 , OC(O)NR c1 R d1 , NR c1 R d1 , NR c1 C(O)R b1 , NR c1 C(O)OR a1 , and NR c1 C(O)NR c1 R d1 , and

R a1 , R b1 , R c1 , and R d1 are each independently selected from H, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 haloalkyl, OH, CN, NO 2 , and CO 2 CH 3 ; wherein said C 1-6 alkyl and C 2-6 alkenyl are each optionally substituted with OH, CN, NO 2 , or CO 2 CH 3 .

2. The method of claim 1 , wherein the cancer is selected from bladder cancer, bone cancer, glioma, breast cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, epithelial cancer, esophageal cancer, Ewing's sarcoma, pancreatic cancer, gallbladder cancer, gastric cancer, gastrointestinal tumors, head and neck cancer, intestinal cancers, Kaposi's sarcoma, kidney cancer, laryngeal cancer, liver cancer, lung cancer, melanoma, prostate cancer, rectal cancer, renal clear cell carcinoma, skin cancer, stomach cancer, testicular cancer, thyroid cancer, and uterine cancer.

3. The method of claim 1 , wherein the cancer is selected from breast cancer, colorectal cancer, and gastric cancer.

4. The method of claim 2 , wherein the breast cancer is triple-negative breast cancer.

5. The method of claim 1 , wherein the cancer is ovarian cancer.

6. The method of claim 1 , wherein R 7 is a peptide capable of selectively delivering R 8 Q-across a cell membrane having an acidic or hypoxic mantle having a pH less than about 6.0.

7. The method of claim 1 , wherein R 7 is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1);

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2);

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3);

Ac-AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTKCG (SEQ ID NO: 4; Pv4); and

AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTC (SEQ ID No. 5; Pv5);

and wherein R 7 is attached to Q through a cysteine residue of R 7 .

8. The method of claim 1 , wherein R 7 is a peptide comprising at least one of the following sequences:

ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1),

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2), and

ADDQNPWRAYLDLLFPTDTLLLDLLWDADECG (SEQ ID NO: 3; Pv3),

and wherein R 7 is attached to Q through a cysteine residue of R 7 .

9. The method of claim 1 , wherein R 7 is a peptide comprising the sequence: ADDQNPWRAYLDLLFPTDTLLLDLLWCG (SEQ ID NO: 1; Pv1).

10. The method of claim 1 , wherein R 7 is a peptide comprising the sequence: AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG (SEQ ID NO: 2; Pv2).

11. The method of claim 1 , wherein R 1 and R 3 together with the carbon atom to which they are attached form a cyclopentyl, cyclohexyl, cycloheptyl, 1,2,3,4-tetrahydronaphthyl, tetrahydrofuranyl, or tetrahydropyranyl.

12. The method of claim 1 , wherein R 1 and R 3 together with the carbon atom to which they are attached form a C 3-7 cycloalkyl group.

13. The method of claim 1 , wherein R 1 and R 3 together with the carbon atom to which they are attached form a cyclohexyl group.

14. The method of claim 1 , wherein Q is:

15. The method of claim 1 , wherein R 2 and R 4 are each H.

16. The method of claim 1 , wherein the compound is selected from:

wherein Pv2 is a peptide comprising the sequence:

(SEQ ID NO: 2)

AEQNPIYWARYADWLFTTPLLLLDLALLVDADECG.

17. The method of claim 1 , wherein the compound is selected from:

wherein Pv1 is a peptide comprising the sequence:

(SEQ ID NO: 1)

ADDQNPWRAYLDLLFPTDTLLLDLLWCG.

18. The method of claim 1 , wherein the compound is:

wherein Pv1 is a peptide comprising the sequence:

(SEQ ID NO: 1)

ADDQNPWRAYLDLLFPTDTLLLDLLWCG.

19. The method of claim 1 , wherein the compound is:

wherein Pv1 is a peptide comprising the sequence:

(SEQ ID NO: 1)

ADDQNPWRAYLDLLFPTDTLLLDLLWCG.

Assignments (3)

Continuity (4)

References Cited (337)